drugset / Trial / NCT02449369

Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee

NCT02449369

Phase 4 Completed 180 enrolled AdventHealth Sagent Pharmaceuticals Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, three-arm, randomized, open-label trial to determine if a new pain control protocol which includes regular dosing of intravenous acetaminophen and orphenadrine for 48 hours after total knee surgery reduces the need for opioid pain medication and reduces average pain scores.

Timeline

Start
2015-04
Primary completion
2016-09
Completion
2016-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule 325 mg Intravenous
Subject Acetaminophen Small molecule 1000 mg Intravenous
Subject Orphenadrine Small molecule 60 mg Intravenous
Subject Orphenadrine Small molecule 100 mg Intravenous
Background Hydromorphone Other / unclassified 0.5 mg
Comparator Oxycodone Other / unclassified 5 mg Oral

Indications

No indication recorded.